Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Novo Nordisk A/S (NYSE:NVO) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Berenberg increased its price target for NVO shares to DKK 325 from DKK 300 while maintaining its Buy rating […]
Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.
Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.
The rally reflects broader positive sentiment toward Viking’s lead candidate, VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms for obesity.
Novo Nordisk A/S (NYSE:NVO) is among the Best Pharmaceutical Stocks. On June 19, Novo Nordisk A/S (NYSE:NVO)’s primary owner, the Novo Nordisk Foundation, reported that it is launching research incubators across Europe to speed up obesity and diabetes drug development. The foundation said it is funding a pan-European program targeting cardiometabolic diseases. It will commit up […]
Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.
Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
European equities traded in the US as American depositary receipts started the week higher late Mond
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
The package delivery giant is building out 27 temperature-controlled facilities across three continents as demand for refrigerated pharmaceuticals grows
With a short percentage of shares outstanding of 0.51%, Novo Nordisk A/S (NYSE:NVO) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares. Earlier, on […]
UK GLP-1 users are shifting spending toward high-protein foods, vitamins and fitness products.
The approval of the first oral pill this month will drive a more powerful shift in consumer habits, PwC found in a study.
Novo Nordisk A/S is investigating claims by cyber extortion group FulcrumSec, which alleges it stole more than a terabyte of data from the pharmaceutical company and is considering selling portions of the information after an unsuccessful $25 million ransom demand. FulcrumSec Claims Months-Long Access To Company Systems Citing a message posted by FulcrumSec on Tuesday, Reuters reported that the group spent more than two months inside Novo Nordisk’s networks collecting data. The hackers claimed t
Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...
Novo Nordisk Foundation has launched CardioMetabolic Bridge, a pan-European initiative focused on translating cardiometabolic research into commercial therapies. The program targets new treatments for obesity, diabetes, and cardiovascular disease, with funding spread over six years and across multiple European countries. The effort aims to move early-stage academic work closer to clinical testing and potential commercial use. Novo Nordisk (CPSE:NOVO B) enters this development with the stock...
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Novo Nordisk Owner Bets Big on Obesity Breakthroughs With New $69 Million Program
Novo Nordisk Foundation commits up to EUR 60 million for drug discovery projects
Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a target of DKK290, just 3.6% above the last closing price of DKK280.10, and maintains a hold...
The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.
June 19 (Reuters) - European shares inched higher on Friday, aided by gains in energy and healthcare stocks as investors remained cautious after U.S.-Iran negotiations to end the Middle conflict
By Stella Qiu SYDNEY, June 19 (Reuters) - Asian shares reversed course and fell on Friday as investors took some money off the table from record rallies in Japan and South Korea, while signs of an
Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
